Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Broad Center for Mendelian Genomics, |
RCV002789969 | SCV003761218 | likely pathogenic | Severe myoclonic epilepsy in infancy | 2023-01-24 | criteria provided, single submitter | curation | The heterozygous p.Val907Gly variant in SCN1A was identified by our study in one individual with epilepsy and congenital myopathy. Trio exome analysis showed this variant to be de novo. The p.Val907Gly variant in SCN1A has not been previously reported in individuals with SCN1A-associated disease. This variant was absent from large population studies. The number of missense variants reported in SCN1A in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. One additional likely pathogenic variant, resulting in a different amino acid change at the same position, p.Val907Phe, has been reported in association with disease in the literature, slightly supporting that a change at this position may not be tolerated (PMID: 27029629). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for SCN1A-associated disease. ACMG/AMP Criteria applied: PS2_Moderate, PM2_Supporting, PM5_Supporting, PP2, PP3 (Richards 2015). |